Today, BioVie announced that the last on-treatment patient visit in the ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of #LongCOVID has been completed. Read more: investors.bioviepharma.com/news/news-de...

Today, we announced positive topline results from the Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage #Parkinson’s disease. The trial successfully met prespecified endpoints. Learn more here: investors.bioviepharma.com/news/news-de...

🧠 Brain fog. 🥱 Fatigue. 🤕 Cognitive impairment. For the millions living with Long COVID, these neurological and neuropsychiatric symptoms are among the most common, chronic, and debilitating. And still without a single FDA-approved treatment. #Neuroinflammation #LongCOVID

#ParkinsonsDisease is the fastest-growing neurodegenerative disorder in the world. Most people think of it primarily as a movement disorder: tremors & motor symptoms. The reality is far more complex. #WorldBrainDay

Findings from @parkinsondotorg.bsky.social's 2026 State of the Community Survey shows what matters most to ppl affected by #Parkinson's: 52% identified non-movement symptoms - sleep disturbances, mood changes & cognitive challenges - among the most pressing concerns, alongside movement symptoms.

Today is #ChronicDiseaseAwarenessDay and Long COVID is a condition that demands our attention. BioVie is committed to advancing research for the millions navigating life with chronic conditions like #LongCOVID.

A new @jama.com study found that the number of people suffering with #longCOVID may be double current estimates. These rates translate to more than 18M Americans, and reflect the growing burden of chronic conditions following COVID-19 infection. #PASC #Neuroinflammation #BrainAwarenessMonth

Parkinson's is the second most common neurodegenerative disease after Alzheimer's disease. #Inflammation and insulin resistance are believed to be key drivers of both #ParkinsonsDisease and Alzheimer's. #AlzheimersBrainAwarenessMonth #NeuroSky

There are no approved treatments for #LongCOVID - yet millions are living with persistent brain fog, fatigue & cognitive impairment driven by neuroinflammation. BioVie's ADDRESS-LC trial is fully enrolled with data expected later this year. #BrainAwarenessMonth

1 in 5 women and 1 in 10 men will develop Alzheimer's in their lifetime. More than 12M Americans are providing unpaid care right now, and the toll on patients, families, and caregivers is profound. #AlzheimersBrainAwarenessMonth #EndALZ

Alzheimer's Association@alzassociation.bsky.social · 3mo ago

Take action during Alzheimer’s & Brain Awareness Month! 💜 Go purple and tell your story using #ENDALZ 🧠 Take the (re)think your brain 6-Step Challenge 🎁 Make a gift 💰 Become a fundraiser 🤝 Volunteer your time 📣 Tell Congress to act Learn more: alz.org/abam.

Nearly 1M Americans are living with #ParkinsonsDisease, with ~ 90K new diagnoses every year. The burden on patients, caregivers, and the healthcare system is immense and will continue to grow. #OlderAmericansMonth

#ICYMI: We held a KOL event to discuss how bezisterim’s MoA - targeting #inflammation & insulin resistance in the brain - addresses the pathology & progression of #Parkinson’s disease. Watch the replay here: youtu.be/v8BGmeVvfm0

Virtual KOL Event to Discuss Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease

YouTube video by BioVie Inc

youtu.be

Enrollment is complete in our Phase 2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected in late summer 2026. Learn more: investors.bioviepharma.com/news/news-de...

BioVie announced today that the last patient evaluation visit has been completed for our SUNRISE-PD Phase 2 trial evaluating bezisterim in early- stage #Parkinson’s disease. Topline data results are expected in Q3 2026. Read more: investors.bioviepharma.com/news/news-de... #Neurology #NeuroSky

During our KOL event last week, Dr. Suzanne de la Monte joined BioVie management to discuss how bezisterim’s MoA addresses the pathology + progression of neurodegenerative disease, including #Parkinson’s disease. Watch the replay: vimeo.com/1190256139/6... #Neuroinflammation #InsulinResistance

26_05_07_BioVie

This is "26_05_07_BioVie" by T5 Live on Vimeo, the home for high quality videos and the people who love them.

vimeo.com

On #CINDAwareness Day we raise awareness & support those battling #MEcfs, #LongCOVID, #Parkinson’s, #Alzheimer's, & other Chronic Immunological and Neurological Diseases. BioVie is committed to advancing potential treatments for chronic neurological disorders. #NeuroSky 💙💚💜

BioVie is hosting a virtual KOL event on May 7 to discuss the P2 study of bezisterim in #Parkinson's disease ahead of upcoming topline data readout. Information & registration details here: lifescievents.com/event/psk38d0/ #Inflammation #InsulinResistance #Neurosky #Neurology

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of Parkinson’s Disease at the upcoming #AANAM in Chicago. Details here: investors.bioviepharma.com/news/news-de... #ParkinsonsDisease #ScientificExchange #Neurology #NeuroSky

We stand with the millions of people living with Parkinson’s to help raise awareness, education, & hope for this progressive neurodegenerative disease that impacts movement, cognition & quality of life. #ParkinsonsAwarenessMonth #ParkinsonsResearch #HopeForPD

The Parkinson's Foundation@parkinsondotorg.bsky.social · 5mo ago

Today is World Parkinson’s Day! 🌎 More than 10 million people worldwide are living with Parkinson’s disease, and in the United States alone, someone new is diagnosed with PD every 6 minutes. (1/2)

Dopamine is one of the most common terms associated with Parkinson’s because it helps mediate smooth, controlled muscle movements. Yet when levels in the brain are too low, motions may become slow, shaky, and halted. Why? #ParkinsonsDiseaseAwarenessMonth

During #ParkinsonsAwarenessMonth we honor people living with PD and their family, friends, nurses, & doctors who stand with them. BioVie is proud to support the Parkinson’s community and is committed to advancing innovative therapies for neurological disorders, including PD.

To all the physicians conducting research, testing new therapies, treating patients, and providing support for people with #neurological & #neurodegenerative diseases & disorders, on #NationalDoctorsDay, we say THANK YOU. #Alz #Parkinsons #longCOVID #Medsky 🩵🩺

#Parkinson’s affects ~1M people in the U.S. w/ prevalence expected to rise with aging population. Yet treatment has changed little in 50 years. Our lead drug candidate, bezisterim (NE3107), addresses the underlying neurodegeneration by targeting #inflammation that causes insulin resistance. Read ⬇️

BioVie targets Parkinson’s at its source with lead drug bezisterim

For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease’s hallmark motor...

proactiveinvestors.com

Some of the most challenging #neurological conditions of our time share a common biology with evidence pointing to #inflammation & insulin resistance as mechanisms underlying #Alzheimer’s, #Parkinson's, & #LongCOVID. #BrainAwarenessWeek

On #LongCOVIDAwarenessDay, we recognize the millions of people still living with the debilitating effects - including #neurological symptoms such as brain fog and fatigue - long after their initial COVID-19 infection.

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of #Parkinson’s at the upcoming #ADPD2026 annual meeting in Copenhagen. Details here: investors.bioviepharma.com/news/news-de... #ScientificExchange #Neurology #Neuroscience $BIVI

Many of the most common #longCOVID symptoms are neurological - #fatigue, #brainfog, cognitive slowing, and memory decline. Research indicates that lingering #inflammation & #biological changes associated with accelerated #aging may be driving these effects in some patients.

How Covid Quietly Rewires the Brain

Researchers keep discovering more about the long-term neurological effects of SARS-CoV-2.

bloomberg.com

A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim’s effects on #inflammation and insulin resistance, two key drivers of #Alzheimer’s, #Parkinson’s, and #LongCOVID. Register here: www.redchip.com/webinar/BIVI... #Neuroscience $BIVI

Our CMO, Dr. Joseph Palumbo joined The Innovators Podcast to discuss BioVie’s mission to develop new treatments for #neurological & #neurodegenerative disorders & what it takes to bring a drug from idea to clinic. Listen here: open.spotify.com/episode/1UZX... #Parkinsons #LongCOVID #Alz

The Innovators Podcast - Joseph Palumbo MD - Chief Medical Officer of BioVie

Spotify video

open.spotify.com

Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on Wednesday, March 4. Register here: investors.bioviepharma.com/news/news-de... #Alzheimers #Parkinsons #LongCOVID #Neuroinflammation #InsulinResistance $BIVI